Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GNPAT | O15228 | 2/20 | 0.36 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.35 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.35 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17973547 | 0.82 | ACE (0.40) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL13881437 | 0.81 | NEU4 (0.32) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL13483252 | 0.77 | CTSK (0.43) | IDO1ITGB3ITGA2B | |
| SCHEMBL14593178 | 0.77 | MTNR1A (0.35) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL15292464 | 0.77 | — | — | |
| SCHEMBL15498915 | 0.74 | LMNA (0.55) | GNPATLMNAFOLH1ITGB3ITGA2B | |
| SCHEMBL18028046 | 0.73 | NEU4 (0.32) | NEU4NEU3NEU2 | |
| SCHEMBL15883863 | 0.70 | MAPT (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL15317631 | 0.70 | — | — | |
| SCHEMBL17193565 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
| US-10624968-B2 | Compounds for treating cancer | Bicyclerd Limited (GB) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624968-B2 | Compounds for treating cancer | TP53, VHL, MYC | MAPT 2318/4885KDM4E 826/4885THRB 4454/4885 |
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | TP53, VHL, MYC | MAPT 2318/4885KDM4E 826/4885THRB 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.